

Extended follow-up of the phase 3 ALPINE study of zanubrutinib versus ibrutinib in R/R CLL/SLL

Authors: Talha Munir,¹ Barbara Eichhorst,² Peter Hillmen,³ Nicole Lamanna,⁴ Susan M. O'Brien,⁵ Constantine S. Tam,⁶ Lugui Qiu,⁷ Tommi Salmi,⁸ Kenneth Wu,⁹ Jennifer R. Brown¹⁰

Affiliations: ¹Leeds Teaching Hospital Nhs Trust, Leeds, United Kingdom; ²University of Cologne, Center for Integrated Oncology Aachen, Germany; ³St James's University Hospital, Leeds, United Kingdom; ⁴Herbert Irving Comprehensive Cancer Center, Columbia University, New York NY, USA; ⁵Chao Family Comprehensive Cancer Center, University of California, Irvine CA, USA; ⁶The Alfred Hospital, Melbourne Victoria, Australia; ⁷State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China; ⁸BeiGene International GmbH, Basel, Switzerland; ⁹BeiGene USA, Inc, San Mateo CA, USA; ¹⁰Dana-Farber Cancer Institute, Boston MA, USA

ABSTRACT

Introduction: In the randomized, phase 3 ALPINE study (NCT03734016), zanubrutinib demonstrated superior progression-free survival (PFS) and overall response rate (ORR) over ibrutinib in patients with R/R CLL/SLL (Brown et al. *NEJM*; 2022). Here, we report updated results after more than 3 years of follow-up.

Methods: Patients with R/R CLL/SLL, ≥ 1 prior therapy, and measurable disease were randomized 1:1 to receive zanubrutinib or ibrutinib. Efficacy was evaluated by the investigator based on 2008 iwCLL criteria; sensitivity analyses were conducted to confirm PFS results. Updated safety analyses were performed. All reported *P*-values are descriptive.

Results: As of 15-September-2023, 652 patients received zanubrutinib (n=327) or ibrutinib (n=325); 194 (59%) remain on zanubrutinib and 152 (47%) on ibrutinib. 130 zanubrutinib-treated and 172 ibrutinib-treated patients discontinued treatment, most commonly due to AE (n=69, zanubrutinib; n=88, ibrutinib) or disease progression (n=51, zanubrutinib; n=62, ibrutinib). At a median study follow-up of 39.0 months, PFS benefit of zanubrutinib was sustained over ibrutinib (HR: 0.68 [95% CI, 0.53-0.86]; *P*=.0011); 36-month PFS rates were 64.9% with zanubrutinib and 54.8% with ibrutinib. PFS benefits with zanubrutinib were observed in the del(17p)/*TP53* subgroup (HR: 0.52 [95% CI, 0.33-0.83]; *P*=.0047); 36-month PFS rates were 58.6% and 41.3%, respectively. The zanubrutinib PFS benefit was confirmed in a sensitivity analysis that included only progression and death events occurring on active treatment (HR: 0.69 [95% CI, 0.50-0.95]; *P*=.0206). ORR was 85.6% and 74.8% (*P*=.0006), CR/CRi rates were 10.7% and 7.1%, and 90.2% and 82.8% achieved PR-L or better with zanubrutinib and ibrutinib, respectively. 64 (19.6%) patients treated with zanubrutinib and 78 (24.0%) with ibrutinib had died (OS HR: 0.75 [95% CI, 0.54-1.05]); median OS was not reached.

The most common any-grade AE with zanubrutinib and ibrutinib was COVID-19 (39.2% vs 27.2%). The most common grade ≥ 3 AE was neutropenia (both 17.3%). Overall cardiac events remained lower with zanubrutinib, including atrial fibrillation/flutter (6.8% vs 16.4%; *P*=.0001). No fatal cardiac events occurred with zanubrutinib, while 6 (1.9%) occurred with ibrutinib.

Conclusions: ALPINE was the first head-to-head comparison of BTK inhibitors to demonstrate PFS superiority. At median follow-up of 39 months, durable PFS benefits with zanubrutinib were observed across major subgroups, including multiple sensitivity analyses. Safety/tolerability profiles were consistent with previous reports; cardiac safety profile remained favorable for zanubrutinib, with no

new safety signals emerging with longer follow-up. These results reconfirm zanubrutinib improved efficacy over ibrutinib and a more favorable cardiac safety profile in patients with R/R CLL/SLL.